The incidence of functional asplenia in sickle-hemoglobin C (SC) disease has not been defined, and the use of prophylactic penicillin to prevent life-threatening septicemia in this disorder is controversial. The percentage of red blood cells with pits (pit count) is a reliable assay of splenic function in other disorders but has not been validated in hemoglobin SC disease. To address these issues, we conducted a prospective, multicenter study of splenic function in persons with hemoglobin SC disease. Baseline clinical data were recorded, and red blood cell pit counts were performed on 201 subjects, aged 6 months to 90 years, with hemoglobin SC; 43 subjects underwent radionuclide liver-spleen scanning. Pit counts greater than 20% were associated with functional asplenia as assessed by liver-spleen scan, whereas pit counts less than 20% were found in subjects with preserved splenic function. Pit counts greater than 20% were present in 0 of 59 subjects (0%) less than 4 years of age, in 19 of 86 subjects (22%) 4 to 12 years of age, and in 25 of 56 subjects (45%) greater than 12 years of age. Other subjects with hemoglobin SC, who had previously undergone surgical splenectomy, had higher pit counts (59.7% +/- 9.5%) than splenectomized subjects without hemoglobinopathy (38.5% +/- 8.8%) or with sickle cell anemia (20.5% +/- 1.9%; P < .001). Two subjects with hemoglobin SC disease (not splenectomized), ages 14 and 15 years, with pit counts of 40.3% and 41.7% died from pneumococcal septicemia. These data indicate that functional asplenia occurs in many patients with hemoglobin SC disease, but its development is usually delayed until after 4 years of age. The pit count is a reliable measure of splenic function in hemoglobin SC disease, but values indicative of functional asplenia (> 20% in our laboratory) are higher than in other disorders. The routine administration of prophylactic penicillin to infants and young children with hemoglobin SC disease may not be necessary.
MULTICENTER STUDY|
April 15, 1995
Functional asplenia in hemoglobin SC disease
PA Lane,
PA Lane
Colorado Sickle Cell Treatment and Research Center, University of Colorado School of Medicine, Denver, USA.
Search for other works by this author on:
JL O'Connell,
JL O'Connell
Colorado Sickle Cell Treatment and Research Center, University of Colorado School of Medicine, Denver, USA.
Search for other works by this author on:
JL Lear,
JL Lear
Colorado Sickle Cell Treatment and Research Center, University of Colorado School of Medicine, Denver, USA.
Search for other works by this author on:
ZR Rogers,
ZR Rogers
Colorado Sickle Cell Treatment and Research Center, University of Colorado School of Medicine, Denver, USA.
Search for other works by this author on:
GM Woods,
GM Woods
Colorado Sickle Cell Treatment and Research Center, University of Colorado School of Medicine, Denver, USA.
Search for other works by this author on:
KL Hassell,
KL Hassell
Colorado Sickle Cell Treatment and Research Center, University of Colorado School of Medicine, Denver, USA.
Search for other works by this author on:
DL Wethers,
DL Wethers
Colorado Sickle Cell Treatment and Research Center, University of Colorado School of Medicine, Denver, USA.
Search for other works by this author on:
DW Luckey,
DW Luckey
Colorado Sickle Cell Treatment and Research Center, University of Colorado School of Medicine, Denver, USA.
Search for other works by this author on:
GR Buchanan
GR Buchanan
Colorado Sickle Cell Treatment and Research Center, University of Colorado School of Medicine, Denver, USA.
Search for other works by this author on:
Blood (1995) 85 (8): 2238–2244.
Citation
PA Lane, JL O'Connell, JL Lear, ZR Rogers, GM Woods, KL Hassell, DL Wethers, DW Luckey, GR Buchanan; Functional asplenia in hemoglobin SC disease. Blood 1995; 85 (8): 2238–2244. doi: https://doi.org/10.1182/blood.V85.8.2238.bloodjournal8582238
Download citation file: